The Lilly Biotechnology Heart in San Diego, California, on March 1, 2023.
Mike Blake | Reuters
Eli Lilly on Thursday reported blended outcomes for the fourth quarter as gross sales of its blockbuster weight reduction and diabetes medicine soared however it noticed decrease realized costs.
The figures have been in line with the preliminary outcomes Eli Lilly shared in January, which disillusioned buyers. Eli Lilly had slashed its 2024 income steering, because it stated demand for its weight reduction and diabetes medicine wouldn’t meet its lofty expectations.
The corporate’s earnings topped Wall Road estimates, however gross sales fell simply quick.
This is what Eli Lilly reported for the interval in contrast with what Wall Road was anticipating, primarily based on a survey of analysts by LSEG:
- Earnings per share: $5.32 adjusted vs. $4.95 anticipated
- Income: $13.53 billion vs. $13.57 billion anticipated
This story is growing. Please test again for updates.